Acasti Pharma Inc. Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Note 6 - Related Parties (Tables)

Note 6 - Related Parties (Tables)

12 Months Ended

Mar. 31, 2018

Statement Line Items [Line Items]

Disclosure of research and development expense [text block]

							Thirteen-months ended				Month ended				Twelve-months ended
			March 31, 2018				March 31, 2017				March 31, 2017				February 28, 2017				February 29, 2016
											(Unaudited)				(Unaudited)
			$				$				$				$				$

Research and development expenses
Supplies and incremental costs			7				-				-				-				5
Shared service agreement			20				60				1				59				366
Total			27				60				1				59				371

General and administrative expenses
Supplies and incremental costs			239				293				16				277				299
Shared service agreement			121				325				25				300				491
Total			360				618				41				577				790
Total related parties expenses			387				678				42				636				1,161

Disclosure of information about key management personnel [text block]

							Thirteen- months ended				Month ended				Twelve- months ended
			March 31, 2018				March 31, 2017				March 31, 2017				February 28, 2017				February 29, 2016
											(Unaudited)				(Unaudited)
			$				$				$				$				$
Compensation			1,754				1,510				146				1,364				688
Severance			-				-				-				-				103
Share-based compensation costs			826				619				78				541				120
Total key management personnel compensation			2,580				2,129				224				1,905				911